24-month follow-up of multiple sclerosis patients treated with cyclophosphamide.
15 patients with remitting-progressive multiple sclerosis received a course of intravenous cyclophosphamide followed by a booster dose every 60 days for 2 years. There were no severe short or medium term side effects. Half of the patients presented clinical stabilization and substantially unchanged Kurtzke rating at 2 year follow-up. Since the aim was stabilization only, our findings argue for continuation of the study in young patients with very short shift.
Millefiorini
E
E
Dipartimento di Scienze Neurologiche, Università La Sapienza, Roma.
Di Giovanni
M
M
Bernardi
S
S
Grasso
M G
MG
Di Giampietro
A
A
Gambi
D
D
D000328:Adult; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012720:Severity of Illness Index
D003520:Cyclophosphamide